Palo Capital’s Amicus Therapeutics FOLD Stock Holding History

Palo Capital’s Portfolio FOLD Stock Details FOLD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-11,607	Closed	-$113K	–	171
2015 Q4	$113K	Buy	+11,607	New	+$105K	0.1%	113

Other funds holding FOLD

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

SAM

Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

JHIU

Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Palo Capital's FOLD Position: Q1 2016 in Review

Palo Capital sold out of Amicus Therapeutics (FOLD) in Q1 2016, closing a stake of 11,607 shares — an estimated $113K sold.

Palo Capital first reported a position in FOLD in Q4 2015 and held it in 1 quarter. The position peaked at $113K in Q4 2015. 128 funds tracked by Wall St. Rank hold FOLD as of Q1 2016.

Palo Capital reported no remaining Amicus Therapeutics position as of Q1 2016 after selling out during the quarter.
Palo Capital sold 11,607 Amicus Therapeutics shares in Q1 2016, an estimated $113K.
Palo Capital first reported a position in Amicus Therapeutics in Q4 2015 and held it in 1 quarter.
Palo Capital's Amicus Therapeutics position peaked at $113K in Q4 2015.
128 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q1 2016.

Based on Palo Capital's 13F filing for Q1 2016, filed 18 Apr 2016.